MedTrace Logo

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

NCT05672537 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-01-05

No results posted yet for this study

Summary

This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC

Conditions

  • Durvalumab
  • Intrahepatic Cholangiocarcinoma
  • Gemcis

Interventions

DRUG

Durvalumab

1500mg intravenous injection for 21d cycle

PROCEDURE

Surgery

Surgery

DRUG

Gemcitabine

gemcitabine 1000mg/m2, D1\&D8, 21d cycle.

DRUG

Cisplatin

cisplatin 25mg/m2, D1\&D8, 21d cycle.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-20
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672537 on ClinicalTrials.gov